Clinical Knowledge Summary: Red light therapy (Longevity Medicine)

 

1. Scope

Covered

– Non-thermal photobiomodulation (PBM) using red (approx. 620–700 nm) and near-infrared (NIR, approx. 700–1100 nm) light from LED or low-level laser sources, delivered transdermally, transcranially, intraoral or ocularly.[1][2]

– Adults attending a private longevity/preventive medicine clinic, including asymptomatic adults seeking healthspan optimisation, adults with cardiometabolic risk, older adults with early cognitive complaints, and physically active adults.

– Adjunctive use alongside NHS primary/secondary care.

Not covered

– Ablative/fractional laser resurfacing, intense pulsed light, UV phototherapy, blue light acne devices, photodynamic therapy (these are photothermal/photochemical, not PBM).

– Bright white light therapy for circadian/affective disorders (a distinct modality acting through melanopsin, not cytochrome c oxidase).[3][4]

– Paediatrics; oncology supportive care protocols (oral mucositis, radiation dermatitis) beyond brief mention.

– Consumer wellness marketing claims (e.g. “reverses biological age”) — no supporting human data.

Key framing statement: No human study has evaluated PBM against mortality, incident multimorbidity, frailty transition or validated epigenetic ageing clocks. All longevity-directed use is therefore extrapolation from disease-specific or surrogate endpoints, and should be positioned as adjunctive, off-label/wellness use with explicit informed consent, or within research.

 

2. Background and pathophysiology

Biological rationale (human mechanistic evidence — moderate to low certainty)

– Red/NIR photons are absorbed by mitochondrial cytochrome c oxidase (complex IV), proposed to displace inhibitory nitric oxide, increase electron transport, ATP output and a transient reactive oxygen species (ROS) signal.[1][2][5]

– The ROS/calcium signal activates redox-sensitive pathways (PI3K/Akt, MAPK, NF-κB, Nrf2) with downstream effects on proliferation, migration, angiogenesis and inflammatory tone.[2][1]

– Secondary mechanisms proposed at the NIA 2023 workshop include modulation of membrane transporters/receptors, light-gated ion channels and latent TGF-β1 activation.[5]

– Human corroboration is indirect: functional near-infrared and MRS studies in ageing brains show restored cytochrome c oxidase activity, altered ATP levels and increased cerebral perfusion after transcranial PBM; a pilot RCT in MCI showed a fall in serum lactate:pyruvate ratio and IL-6 after 6 weeks of 810 nm home tPBM (n=20).[6][7]

Relevance to hallmarks of ageing

– Mitochondrial dysfunction — the only hallmark with any direct human mechanistic signal.[6][7]

– Chronic inflammation — reductions in IL-6 and muscle-damage biomarkers (CK, LDH) after exercise reported in RCT meta-analyses.[8][7]

– Extracellular matrix/skin ageing — increased collagen and dermal remodelling inferred from wrinkle and texture outcomes in RCTs.[9]

– Cellular senescence, telomere biology, epigenetic age — no human in vivo data.

Preclinical only (clearly separated; not a basis for clinical recommendation)

– Red light (630 nm) during early life extended lifespan by approximately 10% in C. elegans via ROS–AMPK-driven mitochondrial quality control.[10]

– In vitro human fibroblast/keratinocyte work: reduced SA-β-gal, p21 and p16 expression, and (with 590 nm) increased telomerase activity and telomere length in serially passaged fibroblasts.[11]

– Rodent models of Parkinson’s disease, retinal degeneration and cognitive ageing show neuroprotection and improved memory.[6][12]

– Interpretation: mechanistic plausibility only. Invertebrate lifespan extension and in vitro senescence markers must not be presented to patients as evidence of human life extension.

 

3. Evidence base and grading

What exists

– Multiple systematic reviews and meta-analyses of RCTs (exercise performance, muscle recovery, skin, pain, wound healing).[8][13][14][15][9]

– Two double-masked sham-controlled multicentre RCTs in dry AMD with 12–24-month follow-up and anatomical endpoints; a Cochrane review of earlier trials.[16][17][18][19]

– Small-to-moderate RCTs of transcranial PBM in MCI and a systematic review of human cognitive studies.[20][21][7][22]

– An international Delphi consensus/evidence-based clinical practice guidance on PBM (JAAD 2025).[23]

– No prospective cohort studies of PBM exposure and mortality, and no RCTs with hard longevity endpoints.[5][12]

GRADE-style summary by outcome

Outcome	Evidence statement	Certainty	Main downgrades	Recommendation
All-cause mortality / lifespan	No human data; invertebrate and epidemiological sunlight-exposure hypotheses only	Very low	Indirectness (animal), no direct evidence	Recommend against claiming benefit; only in research [10], [12]
Epigenetic/biological age, senescent cell burden	No human in vivo data; in vitro senescence-marker changes only	Very low	Indirectness, risk of bias	Only in research [5], [11]
BCVA and drusen/GA progression in early–intermediate dry AMD	2 sham-controlled RCTs; LIGHTSITE III (148 eyes) +6.2 letters at M21 (p=0.0036) and GA incidence 6.8% vs 24.0% at M24 (p=0.007); a 12-month multicentre RCT (138 eyes) showed −0.03 mm³ vs +0.02 mm³ drusen volume and +3.75 letters (95% CI 1.16–6.34)	Moderate	Imprecision (small n), single-device, industry involvement; earlier Cochrane analysis found statistically but not clinically significant 3-month BCVA change	Conditional recommendation — refer to ophthalmology for consideration; do not self-treat the eye [16], [17], [18], [19]
Muscle endurance and recovery (pre-exercise PBM)	Meta-analysis of 34 RCTs: endurance SMD 0.31 (95% CI 0.11–0.51), strength recovery SMD 0.24 (0.10–0.39), CK MD −77.6 U/L; a second meta-analysis (37 studies, 586 participants) found benefit for single-joint endurance (SMD 0.27) and cycling time-to-exhaustion (SMD 0.35) but none for running, swimming or sprint performance	Moderate (endurance/recovery) to Low (whole-body performance)	Small crossover trials, heterogeneous dosing, likely publication bias, no benefit in already physically active subgroups	Conditional recommendation for recovery adjunct; no recommendation for endurance-sport performance [8], [13], [14], [15]
Skin rejuvenation (wrinkles, texture)	Meta-analysis of LED skin studies: red/NIR LED significantly reduced wrinkles and fine lines; a placebo-controlled RCT (n=76) reported 26–36% wrinkle improvement over 4 weeks	Low–Moderate	Short follow-up (<6 months), subjective photographic outcomes, unblinded assessors in some trials	Conditional recommendation — cosmetic benefit only, no inference to systemic ageing [9], [24]
Cognition in MCI / early neurodegeneration	Confirmatory RCT (n=80, 808 nm, 12 weeks): MoCA +3.87 vs −0.74 (p<0.001); RCT (n=93, adults >50 with MCI): MoCA delta 3.20 vs 1.97 (p=0.03) with increased BDNF; pilot RCT (n=20) with MMSE, memory, DMN connectivity and metabolic signals; systematic review of 35 human studies with 83% positive but only half randomised	Low	Small samples, single-centre, short follow-up, heterogeneous devices/parameters, high likelihood of publication bias, practice effects on repeated cognitive testing	Only in research for asymptomatic adults; conditional as adjunct in diagnosed MCI with specialist involvement [7], [20], [21], [22]
Cognition in healthy older adults	Systematic review reports improvements in working memory, inhibition and lexical access, but studies are small and largely single-session	Very low	Indirectness, imprecision, no clinically meaningful endpoints	Only in research [6], [22]
Glycaemia / insulin sensitivity / lipids	Only small crossover and adjunct-to-exercise studies; one crossover trial (n=16, T2DM) showed acute post-exercise glucose reduction; no durable HbA1c or lipid RCT data	Very low	Very small n, surrogate/acute endpoints, no replication	Only in research — do not offer for cardiometabolic risk modification [25], [26]
Safety (adults)	Systematic review + Delphi consensus: PBM is safe in adults and red-light PBM does not induce DNA damage; erythema is the commonest, self-limiting effect; no phototoxicity across 24 months of ocular PBM	Moderate	Short follow-up, under-reporting of AEs in trials	Strong recommendation that PBM is low-risk when parameters are within consensus ranges [1], [17], [23]

 

4. Patient selection and indications

Who might reasonably be offered PBM in a longevity clinic (adjunctive, with consent)

– Adults ≥18 years wanting musculoskeletal recovery support around structured resistance/endurance training — greatest signal in previously sedentary individuals and competitive athletes; no benefit demonstrated in recreationally active individuals.[8]

– Adults with photoageing seeking non-ablative cosmetic improvement.[9]

– Adults with chronic musculoskeletal pain, peripheral neuropathy, androgenetic alopecia, or non-healing wounds/ulcers — the indications with formal consensus support.[23]

– Patients with early or intermediate dry AMD, referred to ophthalmology for device-based PBM rather than treated in a longevity clinic.[16][17][18]

– Patients with specialist-diagnosed MCI who wish to participate in a trial or use tPBM as a monitored adjunct after discussion with the memory service.[20][21]

Not appropriate indications (current evidence)

– Life extension, “biological age reversal”, epigenetic clock modification, senolysis, telomere lengthening.

– Primary prevention of dementia in cognitively normal adults.

– Glycaemic or lipid management in place of guideline-directed therapy.

Exclusions / specialist input required

– Active or suspected cutaneous or systemic malignancy in the treatment field, or undiagnosed pigmented lesions — avoid pending dermatology assessment (proliferative signalling is theoretical but unquantified).[1][2]

– Photosensitising drugs: amiodarone, doxycycline/tetracyclines, thiazides, voriconazole, methotrexate, retinoids, St John’s wort, topical/systemic photosensitisers.

– Photosensitivity disorders: porphyria, SLE with photosensitivity, xeroderma pigmentosum, solar urticaria, polymorphic light eruption.

– Direct ocular exposure to any non-ophthalmic device.

– Retinal disease — ocular PBM only under ophthalmology.

– Pregnancy — avoid direct abdominal/pelvic irradiation (no safety data).

– Epilepsy — avoid pulsed/flickering modes.

– Thyroid gland, active haemorrhage, implanted electronic devices in the beam path where the manufacturer advises against — device-label dependent.

Regulatory and ethical status (UK)

– Home and clinic LED PBM devices are marketed in the UK as UKCA/CE-marked medical devices or as general wellness products; no MHRA or NICE guidance recommends PBM for ageing, longevity or cognitive prevention.

– Any longevity indication is therefore off-label/beyond intended purpose and requires documented informed consent stating: absence of hard-outcome data, cosmetic/functional nature of expected benefit, cost, and that it does not replace guideline-directed care.

– Advertising claims must comply with ASA/CAP rules; claims of life extension or disease prevention are not substantiable.

 

5. Assessment and baseline work-up

History and examination

– Indication and patient’s actual goal (cosmetic, recovery, pain, cognitive) — reframe unrealistic longevity expectations at the outset.

– Full drug and supplement history screening for photosensitisers.

– Skin history: Fitzpatrick phototype, melanoma/NMSC history, prior phototherapy, tattoos or extensive pigmented lesions in the field.

– Ophthalmic history; epilepsy; pregnancy status; autoimmune photosensitivity.

– Skin examination of the intended field; consider dermoscopy or dermatology referral for atypical lesions.

Baseline investigations — tailored, not routine

– Cosmetic/recovery indications: none required beyond clinical assessment. Standardised photography under fixed lighting for skin; validated soreness/DOMS scale and a repeatable performance test (e.g. isokinetic or repetition-to-failure) for musculoskeletal use.[9][8]

– Cognitive indication: formal cognitive testing (MoCA or equivalent) by an appropriately trained clinician, with awareness of practice effects; confirm the diagnostic pathway is under a memory service. Exclude reversible causes (B12, folate, TFTs, calcium, glucose/HbA1c) per usual dementia work-up.[20][21]

– Ocular indication: refer for OCT-based assessment and BCVA in secondary care; do not perform in-clinic.[16][18]

– Cardiometabolic: standard risk assessment (QRISK3, lipids, HbA1c, BP) should proceed as usual, but PBM must not be offered as a risk-modifying treatment.

Risk stratification

Risk tier	Features	Action
Low	Healthy adult, no photosensitisers, no skin lesions, non-ocular field	Proceed; standard consent
Moderate	Fitzpatrick V–VI (higher melanin absorption, greater heat/erythema risk), controlled photosensitivity risk, multimorbidity, frailty	Reduce fluence, extend intervals, review after 2–4 sessions
High	Photosensitising drug, active malignancy in field, retinal disease, pregnancy, undiagnosed lesion, uncontrolled epilepsy	Avoid or defer pending specialist advice

Baseline documentation (minimum dataset)

– Device make/model, wavelength(s) in nm, output irradiance (mW/cm²) at the stated treatment distance, treatment area (cm²), exposure time, calculated fluence (J/cm²), distance, and whether continuous or pulsed.

– Anatomical field(s) treated and eye protection used.

– Chosen primary outcome measure and its baseline value.

– Consent record explicitly noting off-label/unlicensed use for the stated goal.

 

6. Dosing regimens and practical implementation

Core parameters (consensus/expert level, not derived from dose-finding RCTs)

– Commonly recommended: power density <100 mW/cm² and 4–10 J/cm² at target tissue, though surface fluences up to 50 J/cm² are used by some groups.[27]

– Biphasic dose–response is the central practical principle: tissues rich in mitochondria (muscle, brain, nerve, retina) respond to lower doses, and negative trials in these tissues more often reflect overdosing than underdosing.[27][2]

– Reported red-light power densities across the literature span 10–5000 mW/cm² with exposures of 10–3000 s — this heterogeneity is the main obstacle to protocol standardisation.[28][2]

Regimens with the most robust human support

Indication	Protocol (as used in trials)	Evidence tier
Pre-exercise muscle endurance/recovery	Red and/or NIR LED or laser applied to the target muscle groups immediately (minutes) before exercise; typical trial ranges 20–60 J per site; sessions tied to training days	Meta-analyses of RCTs [8], [13], [15]
Facial photoageing	660 nm LED panel/mask, approx. 6 mW/cm², approx. 8 J/cm², 20–21 min, 2–3 times weekly for 4 weeks; combined red + NIR appears at least as effective as either alone	RCTs within meta-analysis [9], [24]
Dry AMD (ophthalmology only)	Multiwavelength 590/660/850 nm, 9 sessions delivered 3×/week over 3–5 weeks, repeated every 4 months	LIGHTSITE III [16], [17]
MCI (research/specialist adjunct)	808–810 nm to bilateral dorsolateral prefrontal cortex, 20 min/session, 6 days per week for 6–12 weeks; clinical protocols commonly cite 810 nm, 20–25 mW/cm², 1–10 J/cm²	Small RCTs [7], [20], [22]

Titration and course structure

– Start at the lower end of the fluence range, treat 2–3 times weekly, and reassess at 4 weeks against the pre-specified outcome.

– Do not escalate fluence in the absence of response in high-mitochondrial tissue; consider reducing dose or increasing the interval, given the biphasic curve.[27]

– Typical maintenance after an initial 4–12 week course: 1–2 sessions weekly, or repeated short courses (the AMD model of intermittent 3–5 week blocks every 4 months is the only trial-validated maintenance schedule).[17]

Hardware and setting requirements

– Use a device with published, verifiable irradiance at a stated distance; many consumer devices overstate output. Record distance precisely, since irradiance falls with the square of distance.

– Wraparound eye protection for all facial/transcranial treatments; never look into the array.

– Non-thermal operation: skin should feel warm, not hot. Stop for pain or discomfort.

– Full-body “red light beds” have essentially no controlled outcome data for systemic ageing endpoints — treat as unvalidated.

Regimens requiring explicit caution (extrapolated from early-phase or preclinical data)

– Whole-body high-irradiance panels for “mitochondrial health”.

– Daily long-duration high-fluence exposure.

– Transcranial PBM in cognitively normal adults.

– Any protocol targeting biological-age biomarkers.

 

7. Monitoring, safety and follow-up

Monitoring plan

– Clinical: skin in the treated field at each visit (erythema, oedema, blistering, pigmentary change); headache, eye strain or photophobia after transcranial/facial use; sleep quality if treating in the evening.

– Outcome tracking: re-measure the single pre-specified primary outcome — standardised photography (skin), soreness/performance measure (musculoskeletal), pain score, or cognitive score where specialist-directed.

– Laboratory/imaging: none routinely indicated. Ophthalmic OCT/BCVA monitoring applies only to ocular protocols and is done in secondary care.[16]

– Ageing biomarkers: epigenetic clocks, senescence panels and telomere length should not be used to guide PBM decisions outside research — no evidence links PBM to change in these measures, and they have not been shown to respond meaningfully to it.

Timepoints

– Short term (2–4 weeks): tolerability review; skin check.

– Medium term (8–12 weeks): formal reassessment against the primary outcome. Stop if no meaningful benefit — continuing an ineffective, self-funded intervention is not justifiable.

– Long term (6–12 monthly): annual skin surveillance if long-term facial/body use; reconsent and reappraise against updated evidence.

Adverse effects

– Common (self-limiting): transient erythema in the treated field — the most frequently reported cutaneous effect; mild warmth; transient eye discomfort or headache with facial/transcranial use. In the tPBM pilot RCT, adverse events occurred in 10/20 participants but were mild and no more frequent than sham.[1][23][7]

– Uncommon: temporary hyperpigmentation (more likely in darker phototypes), dryness, tightness, exacerbation of melasma with heat-generating devices, insomnia if used late in the evening.

– Serious/rare: thermal burn from a malfunctioning or excessively close high-irradiance device; retinal injury from direct viewing of high-power NIR sources (NIR does not trigger the blink/aversion reflex — this is the single most important practical hazard).

– Reassurance: the JAAD international consensus concluded PBM is a safe modality in adults and that red-light PBM does not induce DNA damage; 24 months of ocular PBM produced no phototoxicity.[23][17]

Actions on abnormal findings

– Erythema persisting >24 h: reduce fluence or frequency by half.

– Blistering, burn or pain: stop, treat as thermal injury, check device output and distance before any restart.

– New or changing pigmented lesion in the field: stop and refer to dermatology (2-week-wait pathway if suspicious).

– Visual symptoms: stop and refer to ophthalmology.

– No benefit at 12 weeks: discontinue.

Interactions

– Drug: photosensitising drugs (see section 4) — the principal interaction; review before every new course.

– Intervention: avoid combining with same-day chemical peels, ablative laser, microneedling or retinoid initiation in the same field; sequence with a recovery interval.

– Comorbidity: melasma and rosacea may flare with heat; use lower-irradiance, cooler protocols.

Special populations

– Pregnancy/breastfeeding: no safety data; avoid abdominal, pelvic and breast fields. Limited peripheral musculoskeletal use only if clearly justified.

– Renal/hepatic impairment: no systemic drug exposure; no dose adjustment needed. Review photosensitising medicines.

– Frailty and extremes of age: thinner, more fragile skin and reduced thermal sensation increase burn risk — use lower irradiance, shorter exposures, and supervise rather than issue home devices. No efficacy data on frailty, sarcopenia or falls.

– Immunosuppression/transplant recipients: heightened skin cancer surveillance needs; dermatology input before chronic use.

 

8. Contraindications and cautions

Absolute

– Direct irradiation of the eye with any device not specifically designed and regulated for ocular PBM.

– Known or suspected malignancy within the treatment field (until assessed).

– Active photosensitivity disorder (porphyria, xeroderma pigmentosum, solar urticaria).

– Concurrent photodynamic therapy or systemic photosensitising agent given for therapeutic photosensitisation.

Relative / specialist advice required

– Photosensitising medication use.

– Pregnancy (abdominal/pelvic fields).

– Epilepsy with photosensitivity (pulsed devices).

– Retinal disease, prior retinal surgery.

– Melasma, active rosacea, recent field procedures.

– History of melanoma or multiple NMSC.

– Significant frailty, sensory neuropathy or impaired thermal sensation in the field.

– Implanted devices where the manufacturer contraindicates.

Where harm is likely to outweigh benefit on current evidence

– Using PBM as a substitute for statins, antihypertensives, glucose-lowering therapy, exercise or smoking cessation.

– High-cost, high-frequency, indefinite protocols marketed for “biological age reversal”.

– Transcranial PBM self-administered without diagnosis in cognitively normal adults.

– Any use that delays investigation of a symptom (a changing skin lesion, visual loss, cognitive decline).

 

9. Practical management scenarios

Scenario A — 52-year-old with obesity, hypertension and prediabetes requesting red light therapy for “metabolic health and longevity”

– Recommendation: Avoid for the stated indication (Recommend against / Only in research). No RCT evidence supports durable glycaemic, lipid or cardiovascular benefit; available data are small acute crossover studies.[25][26]

– Assessment: full cardiometabolic work-up (BP, lipids, HbA1c, ALT, QRISK3), lifestyle and sleep history, medication review for photosensitisers.

– Shared decision-making: state plainly that PBM has not been shown to alter cardiometabolic risk or mortality, and that resources are better directed to guideline-based therapy. Document.

– If the patient still wishes to proceed for an evidence-supported secondary purpose (e.g. supporting a new resistance-training programme, where meta-analytic benefit exists in previously sedentary individuals): offer a time-limited 8–12 week trial of pre-exercise limb PBM at ≤100 mW/cm², 4–10 J/cm², on training days, alongside guideline-directed cardiometabolic management.[8]

– Monitoring: adherence to exercise, soreness/performance measure, skin check at 4 weeks; usual cardiometabolic follow-up at 3–6 months.

– Stop/escalate: discontinue PBM if no functional benefit at 12 weeks; escalate cardiometabolic management to guideline thresholds irrespective of PBM.

Scenario B — 81-year-old with frailty, multimorbidity, polypharmacy and subjective memory complaints

– Recommendation: Restrict to research, or specialist-linked adjunct only (Only in research for prevention; Conditional if formally diagnosed MCI). RCT evidence in MCI is promising but small, short and single-centre; there are no data in frailty or multimorbidity.[20][21][7]

– Assessment: first exclude reversible contributors and refer to the memory service for formal diagnosis; medication review specifically for photosensitisers and anticholinergic burden; skin fragility and thermal sensation assessment; ophthalmic history.

– Shared decision-making: clarify that PBM is not recommended by NICE for cognitive impairment, that the effect sizes come from small trials at risk of practice effects, and that it must not delay standard assessment.

– If proceeding as adjunct with memory-service awareness: 810 nm transcranial device, 20 min per session, 6 days/week for 12 weeks, supervised or carer-assisted, with eye protection.[20]

– Monitoring: carer-reported function and MoCA at baseline and 12 weeks (interpreting change cautiously); skin and tolerability review at 2 and 6 weeks.

– Stop/escalate: stop for any burn, agitation, sleep disruption or absence of functional benefit at 12 weeks; refer promptly if cognition declines.

Scenario C — 68-year-old with intermediate dry AMD under ophthalmology, asking about home red light devices

– Recommendation: Do not offer home devices; refer back to ophthalmology for consideration of validated ocular PBM (Conditional recommendation, specialist setting only).

– Rationale: benefit in AMD is tied to a specific multiwavelength ophthalmic delivery system with a defined 9-session, 4-monthly schedule, with a +6.2-letter BCVA gain at M21 and reduced progression to geographic atrophy (6.8% vs 24.0% at M24), supported by an independent 12-month multicentre RCT showing drusen volume reduction and +3.75 letters. Home devices are not equivalent, are not regulated for ocular exposure, and carry a real risk of retinal injury.[17][18]

– Stepwise: confirm AREDS category and current supplementation; write to the ophthalmologist; document advice against unregulated home ocular exposure; continue smoking cessation, blood pressure control and AREDS2 supplementation as directed.

– Monitoring: ophthalmology-led OCT and BCVA; safety-net for sudden distortion or central vision loss.

Scenario D — 34-year-old competitive endurance athlete seeking performance gains

– Recommendation: Consider for recovery; do not offer for endurance-race performance (Conditional / no recommendation respectively). Meta-analysis shows benefit for single-joint endurance and cycling time-to-exhaustion, but no effect on running or swimming performance or sprint metrics; benefit is also absent in already physically active individuals in a separate meta-analysis.[13][8]

– Practical: if used, apply pre-exercise to target muscle groups within the consensus parameter range; track DOMS and session quality; discontinue at 8 weeks if no perceived recovery benefit. Note anti-doping status is unaffected (PBM is not a prohibited method), but device claims should be checked against event rules.

 

10. Research gaps and future directions

– Hard endpoints: no trial has assessed mortality, incident cardiovascular disease, dementia incidence, frailty transition or disability. This is the fundamental gap for longevity claims.[5][12]

– Ageing biomarkers: no human study links PBM to epigenetic clocks, senescent cell burden (p16, SASP), or telomere dynamics in vivo; in vitro signals require translational testing.[11]

– Dose standardisation: the biphasic dose–response is well described but poorly quantified in humans; formal dose-finding studies with tissue-level dosimetry are the highest-priority methodological need.[27][28][2]

– Device validation: independent measurement of consumer device irradiance and spectral output is lacking; reported outputs are frequently unverified.

– Cognition: adequately powered, multicentre, double-blind trials in MCI with biomarker and imaging endpoints and ≥12-month follow-up are needed before any preventive use.[20][7][22]

– Cardiometabolic: no adequately powered RCT with HbA1c, insulin sensitivity by clamp, or lipids as pre-specified primary endpoints over ≥12 weeks.

– Long-term safety: cumulative multi-year exposure data, particularly cutaneous oncological safety in high-frequency users and in immunosuppressed patients, are absent despite short-term reassurance.[23]

– Where practice should be trial-limited: transcranial PBM in healthy adults, whole-body PBM for systemic ageing endpoints, and any PBM protocol marketed as biological-age modifying. Clinics offering these outside trials should at minimum maintain a prospective registry with standardised parameter and outcome capture.

 

References

1. Photobiomodulation CME Part I: Overview and Mechanism of Action. Maghfour J, Ozog DM, Mineroff J, et al. Journal of the American Academy of Dermatology. 2024;91(5):793-802. doi:10.1016/j.jaad.2023.10.073.
2. Mechanisms of Action and Clinical Research Progress of Photobiomodulation. Shi G, Wei K, Wang R, et al. Journal of Photochemistry and Photobiology. B, Biology. 2026;282:113529. doi:10.1016/j.jphotobiol.2026.113529.
3. Circadian desynchrony and glucose metabolism. Speksnijder EM, Bisschop PH, Siegelaar SE, Stenvers DJ, Kalsbeek A. Journal of Pineal Research. 2024;76(4):e12956. doi:10.1111/jpi.12956.
4. Effects of Light Therapy on Mood and Insulin Sensitivity in Patients With Type 2 Diabetes and Depression: Results From a Randomized Placebo-Controlled Trial. Brouwer A, van Raalte DH, Nguyen HT, et al. Diabetes Care. 2019;42(4):529-538. doi:10.2337/dc18-1732.
5. Light Buckets and Laser Beams: Mechanisms and Applications of Photobiomodulation (PBM) Therapy. Frankowski DW, Ferrucci L, Arany PR, et al. GeroScience. 2025;47(3):2777-2789. doi:10.1007/s11357-025-01505-z.
6. Photobiomodulation in the Aging Brain: A Systematic Review From Animal Models to Humans. Rodríguez-Fernández L, Zorzo C, Arias JL. GeroScience. 2024;46(6):6583-6623. doi:10.1007/s11357-024-01231-y.
7. A Multimodal Evaluation of Transcranial Photobiomodulation in Mild Cognitive Impairment: Cognitive, Metabolic, and Neuroimaging Outcomes of a Pilot Randomized Controlled Trial. Rashidi-Ranjbar N, Churchill NW, Jerkic M, et al. Journal of Alzheimer’s Disease : JAD. 2026;112(3):1445-1458. doi:10.1177/13872877261453911.
8. Can Pre-Exercise Photobiomodulation Improve Muscle Endurance and Promote Recovery From Muscle Strength and Injuries in People With Different Activity Levels? A Meta-Analysis of Randomized Controlled Trials. Li BM, Qiu DY, Ni PS, et al. Lasers in Medical Science. 2024;39(1):132. doi:10.1007/s10103-024-04079-y.
9. Utilization of light‐emitting diodes for skin therapy: Systematic review and meta‐analysis. Ngoc LTN, Moon JY, Lee YC. Photodermatology, Photoimmunology & Photomedicine. 2023;39(4):303-317. doi:10.1111/phpp.12841.
10. Early-Life Red Light Exposure Extends Lifespan in C. Elegans Through ROS-AMPK-Driven Mitochondrial Reprogramming. Zhu Y, Lin X, Wang H, et al. Aging and Disease. 2025;:AD.2025.0791. doi:10.14336/AD.2025.0791.
11. The Impact of Lasers and Energy‐Based Devices on Cellular Senescence: A Systematic Review. Kelm RC, Murphrey MB. Lasers in Surgery and Medicine. 2026;58(1):5-20. doi:10.1002/lsm.70079.
12. Sunlight and Health: Shifting the Focus From Vitamin D3 to Photobiomodulation by Red and Near-Infrared Light. Heiskanen V, Pfiffner M, Partonen T. Ageing Research Reviews. 2020;61:101089. doi:10.1016/j.arr.2020.101089.
13. Deconstructing the Ergogenic Effects of Photobiomodulation: A Systematic Review and Meta-Analysis of Its Efficacy in Improving Mode-Specific Exercise Performance in Humans. Dutra YM, Malta ES, Elias AS, Broatch JR, Zagatto AM. Sports Medicine (Auckland, N.Z.). 2022;52(11):2733-2757. doi:10.1007/s40279-022-01714-y.
14. Comparison Between Cryotherapy and Photobiomodulation in Muscle Recovery: A Systematic Review and Meta-Analysis. Ferlito JV, Ferlito MV, Leal-Junior ECP, Tomazoni SS, De Marchi T. Lasers in Medical Science. 2022;37(3):1375-1388. doi:10.1007/s10103-021-03442-7.
15. Effects of Low-Level Laser Therapy on Muscular Performance and Soreness Recovery in Athletes: A Meta-Analysis of Randomized Controlled Trials. Luo WT, Lee CJ, Tam KW, Huang TW. Sports Health. 2022 Sep-Oct;14(5):687-693. doi:10.1177/19417381211039766.
16. LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System. Boyer D, Hu A, Warrow D, et al. Retina (Philadelphia, Pa.). 2024;44(3):487-497. doi:10.1097/IAE.0000000000003980.
17. Long-Term Efficacy and Safety of Photobiomodulation in Dry Age-Related Macular Degeneration (Lightsite Iii: 24-Month Analysis). Jaffe GJ, Boyer D, Hu A, et al. Retina (Philadelphia, Pa.). 2026;46(5):783-795. doi:10.1097/IAE.0000000000004822.
18. 12-Month Outcomes of Photobiomodulation in Dry Age-Related Macular Degeneration: A Prospective Multicentre Randomised Double-Masked Controlled Clinical Trial. Iovino C, Borrelli E, Coco G, et al. The British Journal of Ophthalmology. 2026;:bjo-2025-328389. doi:10.1136/bjo-2025-328389.
19. Photobiomodulation for Non-Exudative Age-Related Macular Degeneration. Henein C, Steel DH. The Cochrane Database of Systematic Reviews. 2021;5:CD013029. doi:10.1002/14651858.CD013029.pub2.
20. Home-Based Transcranial Photobiomodulation Improves Cognitive Function in Mild Cognitive Impairment Due to Alzheimer’s Disease: A Randomized, Double-Blind, Placebo-Controlled Confirmatory Trial. Chun H, Lee HW, Hong SB, Ha SS, Yoon KJ. Journal of Alzheimer’s Disease : JAD. 2026;111(4):1699-1707. doi:10.1177/13872877261443973.
21. Transcranial Photobiomodulation Increases Cognition and Serum BDNF Levels in Adults Over 50 years: A Randomized, Double-Blind, Placebo-Controlled Trial. de Oliveira BH, Lins EF, Kunde NF, et al. Journal of Photochemistry and Photobiology. B, Biology. 2024;260:113041. doi:10.1016/j.jphotobiol.2024.113041.
22. Can Transcranial Photobiomodulation Improve Cognitive Function? A Systematic Review of Human Studies. Lee TL, Ding Z, Chan AS. Ageing Research Reviews. 2023;83:101786. doi:10.1016/j.arr.2022.101786.
23. Evidence-Based Consensus on the Clinical Application of Photobiomodulation. Maghfour J, Mineroff J, Ozog DM, et al. Journal of the American Academy of Dermatology. 2025;:S0190-9622(25)00659-0. doi:10.1016/j.jaad.2025.04.031.
24. Comparison of the Effects of 2 Frequencies of Application of Photobiomodulation on Facial Rejuvenation: Controlled, Randomized, and Double-Blind Clinical Trial. Bragato EF, Pires JA, Momolli M, et al. Medicine. 2023;102(5):e32514. doi:10.1097/MD.0000000000032514.
25. Effects of Light-Emitting Diode Therapy (LEDT) on Cardiopulmonary and Hemodynamic Adjustments During Aerobic Exercise and Glucose Levels in Patients With Diabetes Mellitus: A Randomized, Crossover, Double-Blind and Placebo-Controlled Clinical Trial. Francisco CO, Beltrame T, Hughson RL, et al. Complementary Therapies in Medicine. 2019;42:178-183. doi:10.1016/j.ctim.2018.11.015.
26. The potential of phototherapy to reduce body fat, insulin resistance and “metabolic inflexibility” related to obesity in women undergoing weight loss treatment. Sene-Fiorese M, Duarte FO, de Aquino Junior AE, et al. Lasers in Surgery and Medicine. 2015;47(8):634-42. doi:10.1002/lsm.22395.
27. Review of Light Parameters and Photobiomodulation Efficacy: Dive Into Complexity. Zein R, Selting W, Hamblin MR. Journal of Biomedical Optics. 2018;23(12):1-17. doi:10.1117/1.JBO.23.12.120901.
28. Photobiomodulation Therapy: Survey and Principal Study Leading to Design Rules for Implants. Kaffash Z, Saha R, Mirbozorgi SA, Faezipour M, Mirbozorgi SA. IEEE Transactions on Bio-Medical Engineering. 2025;72(7):2237-2248. doi:10.1109/TBME.2025.3538650.